The European Commission has approved Sandoz’s biosimilar Zessly (infliximab) to treat all indications of its reference medicine…
Articles by Ana de Barros PhD
Ontario, along with other regions in Canada, will now reimburse Cosentyx (secukinumab) under its public drug program for certain…
The European Medicines Agency has accepted for review Lupin‘s marketing authorization application for YLB113, a biosimilar of etanercept that is marketed by …
Mylan and Fujifilm Kyowa Kirin Biologics are partnering to commercialize a biosimilar to Humira (adalimumab) after obtaining…
The Canadian provinces of Manitoba, Saskatchewan, Alberta, and Newfoundland have joined others in adding Sandoz’s biosimilar Erelzi (etanercept) to provincial…
Coinciding with Spondyloarthritis Awareness Month, the Spondylitis Association of America (SAA) is kicking off a national awareness campaign to…
The U.S. Food and Drug Administration (FDA) has approved Pfizer’s Ixifi (infliximab-qbtx), a biosimilar to Janssen Biotech’s…
Novartis has initiated a Phase 4 clinical trial to evaluate the impact of increasing the dose of Cosentyx…
In vitro diagnostics and theranostics company Theradiag is partnering with the U.S. biotech company Biogen to provide Lisa Tracker kits…
Boehringer Ingelheim announced that the European Commission has granted marketing authorization for Cyltezo, a biosimilar to Humira (adalimumab), for the…